Literature DB >> 9285290

Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease.

M Popović1, N Popović, K Jovanova-Nesić, D Bokonjić, S Dobrić, V S Kostić, N Rosić.   

Abstract

The present study was performed to investigate and compare the effect of acetylcholinesterase inhibitor, physostigmine (0.045, 0.060 and 0.075 mg/kg sc, 30 min before the tests) and Ca-antagonist, verapamil (1.0, 2.5, 5.0 and 10.0 mg/kg sc, 30 min before the tests), on two-way active avoidance (AA) learning (acquisition and performance) in nucleus basalis magnocellularis (NBM)-lesioned rats. Bilateral electrolytic lesions of NBM induced significant decrease of acquisition and performance of AA responses in rats. Physostigmine (0.060 mg/kg) significantly improved only acquisition of AA, while verapamil (2.5 and 5.0 mg/kg) significantly improved both type of AA behavior in NBM-lesioned rats. These results suggest that altered calcium homeostasis might play significant role in pathogenesis of experimental induced Alzheimer's disease (AD) and that administration of calcium antagonist such as verapamil might successfully ameliorate disturbances of learning and memory appeared after lesions of NBM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285290     DOI: 10.3109/00207459709000628

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  6 in total

1.  Verapamil prevents, in a dose-dependent way, the loss of ChAT-immunoreactive neurons in the cerebral cortex following lesions of the rat nucleus basalis magnocellularis.

Authors:  Miroljub Popović; Maria Caballero-Bleda; Natalija Popović; Luis Puelles; Thomas van Groen; Menno P Witter
Journal:  Exp Brain Res       Date:  2005-11-23       Impact factor: 1.972

2.  Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.

Authors:  Saravanaraman Ponne; Chinnadurai Raj Kumar; Rathanam Boopathy
Journal:  Metab Brain Dis       Date:  2019-11-05       Impact factor: 3.584

3.  Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome.

Authors:  Qing Chang; Paul E Gold
Journal:  Neurobiol Learn Mem       Date:  2007-07-20       Impact factor: 2.877

4.  Verapamil Blocks Scopolamine Enhancement Effect on Memory Consolidation in Passive Avoidance Task in Rats.

Authors:  Verónica Giménez De Béjar; María Caballero Bleda; Natalija Popović; Miroljub Popović
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

Review 5.  Verapamil and Alzheimer's Disease: Past, Present, and Future.

Authors:  Natalija Popović; Nicanor Morales-Delgado; David Vidal Mena; Antonia Alonso; María Pascual Martínez; María Caballero Bleda; Miroljub Popović
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

6.  Verapamil Ameliorates Motor Neuron Degeneration and Improves Lifespan in the SOD1G93A Mouse Model of ALS by Enhancing Autophagic Flux.

Authors:  Xiaojie Zhang; Sheng Chen; Kaili Lu; Feng Wang; Jiangshan Deng; Zhouwei Xu; Xiuzhe Wang; Qinming Zhou; Weidong Le; Yuwu Zhao
Journal:  Aging Dis       Date:  2019-12-01       Impact factor: 6.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.